Jazz Pharmaceuticals (JAZZ) Tops Q4 EPS by 81c, provides guidance
Tweet
Share
E-mail
Get Alerts JAZZ Hot Sheet
Price: $240.07 --0%
EPS Growth %: -20.5%
Financial Fact:
Selling, general and administrative: 124.37M
Today's EPS Names:
SUNB, CULP, KFY, More
EPS Growth %: -20.5%
Financial Fact:
Selling, general and administrative: 124.37M
Today's EPS Names:
SUNB, CULP, KFY, More
Join SI Premium – FREE
Jazz Pharmaceuticals (NASDAQ: JAZZ) reported Q4 EPS of $6.60, $0.81 better than the analyst estimate of $5.79. Revenue for the quarter came in at $1.1 billion versus the consensus estimate of $1.06 billion.
GUIDANCE:
Jazz Pharmaceuticals sees FY2025 EPS of $22.50-$24.00, versus the consensus of $22.03.
For earnings history and earnings-related data on Jazz Pharmaceuticals (JAZZ) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Chewy (CHWY) Reports In-Line Q2 EPS, Offers Guidance
- ABM Industries (ABM) Reports In-Line Q3 EPS; raises guidance
- Chime Financial (CHYM) PT Raised to $50 at Canaccord
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
